24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

112s Cancer Prevention/Epidemiology<br />

1608 General Poster Session (Board #10B), Sat, 1:15 PM-5:15 PM<br />

<strong>American</strong> BRCA outcomes and utilization <strong>of</strong> testing (ABOUT) study.<br />

Presenting Author: Rebecca Sutphen, Epidemiology Center, University <strong>of</strong><br />

South Florida Morsani College <strong>of</strong> Medicine, Tampa, FL<br />

Background: An estimated 100,000 individuals currently undergo genetic<br />

testing for hereditary susceptibility to breast and ovarian cancer annually in<br />

the U.S., yet little is known about their characteristics, testing experience<br />

or outcomes. Research in this high-risk group has been limited to patients<br />

recruited at academic medical centers where case ascertainment, health<br />

services delivery, decision-making and, quite likely, outcomes are different<br />

from those in the community setting where the majority <strong>of</strong> individuals<br />

currently receive healthcare services. Methods: Eligible subjects include<br />

10,000 consecutive individuals requesting BRCA testing through the<br />

nation’s third-largest health insurer, Aetna, beginning in December, 2011.<br />

De-identified data are analyzed from each test request form submitted by<br />

the ordering provider. Each eligible subject is mailed a study packet<br />

inviting them to complete a questionnaire (by mail, online or telephone)<br />

designed to investigate informational and healthcare services, test results,<br />

knowledge, risk perception and medical intentions. Results: Of 442<br />

subjects contacted during the first two weeks <strong>of</strong> accrual, 143 (32%) have<br />

completed the questionnaire to date. Similar to Aetna member demographics,<br />

7% are African-<strong>American</strong> and 7% report Hispanic ethnicity. Based on<br />

Chi-Square tests, there were no differences between respondents and<br />

non-respondents with regard to age (51% under age 50), race, ethnicity or<br />

personal history <strong>of</strong> cancer (58%). Among respondents, deleterious mutations<br />

were identified in 8%. Testing for a known familial mutation was<br />

performed in 8%. Among women with breast cancer, 13% were undergoing<br />

testing prior to initial surgical treatment. Updated results from 3000<br />

eligible subjects will be presented. Conclusions: This innovative, academicindustry<br />

collaboration enables an unprecedented investigation <strong>of</strong> significant<br />

issues surrounding individuals at increased risk for hereditary breast<br />

and ovarian cancer and undergoing genetic testing in the U.S. The results<br />

will guide the development and dissemination <strong>of</strong> more targeted decisionsupport<br />

tools and strategies to improve medical outcomes for such<br />

individuals.<br />

1610 General Poster Session (Board #10D), Sat, 1:15 PM-5:15 PM<br />

Health and quality <strong>of</strong> life (QOL) issues in four groups <strong>of</strong> lung cancer<br />

patients: Low-dose computed tomography (LDCT) screened, chest x-ray<br />

detected, incidentally found, and routinely diagnosed. Presenting Author:<br />

Ping Yang, Mayo Clinic, Rochester, MN<br />

Background: Low dose computed tomography (LDCT) scans have reduced<br />

lung cancer deaths by 20.3% in high risk populations, although there is an<br />

unknown balance between the benefits and harms <strong>of</strong> LDCT scans as a<br />

screening tool. Our purpose was to compare health-related QOL issues<br />

among lung cancer patients who were initially detected by LDCT scans; 4<br />

comparison groups included: lung cancer diagnosed by a screening chest<br />

X-ray, as an incidental finding from procedures taken for other medical<br />

reasons, or based on symptoms indicative for lung cancer and routinely<br />

diagnosed, and individuals who were LDCT screened but found no lung<br />

cancer (controls who participated in Mayo’s lung cancer CT screening trial).<br />

Methods: A total <strong>of</strong> 1,658 lung cancer patients (cared at Mayo Clinic) in the<br />

4 groups (37, 151, 389, and 1081 respectively) and 488 controls were<br />

compared on following patient-reported outcomes (collected via validated<br />

tools): overall QOL, four symptoms (cough, pain, dyspnea, fatigue), mental/<br />

physical/ emotional/ social/ spiritual QOL, and other concerns (e.g., family/<br />

friends/ financial/ legal). A clinically significant deficit was defined as at<br />

least 10-points in difference (or �50 points) on a 0-100 scale. The rates <strong>of</strong><br />

deficits were compared via Fisher’s exact tests and average QOL values via<br />

Kruskal-Wallis tests. Results: Overall QOL and individual symptoms were<br />

significantly worse (p�0.05) in all lung cancer groups than in controls,<br />

except for pain. LDCT-screened patients reported the greatest deficit<br />

among the 4 lung cancer groups in physical (41%), emotional (24%),<br />

social (38%), and spiritual QOL (24%); whereas chest X-ray detected<br />

patients had the least deficit in overall QOL (22%) and pain (32%). All 4<br />

lung cancer groups experienced much worse fatigue (52-64%) than the<br />

controls (32%). Conclusions: Our preliminary results suggest that LDCTscreening<br />

detected lung cancer patients reported a different QOL pr<strong>of</strong>ile<br />

from other lung cancer patients and non-lung cancer controls. The clinical<br />

course, smoking behavior, and QOL related health issues associated with<br />

LDCT screening for lung cancer warrant thorough investigation.<br />

1609 General Poster Session (Board #10C), Sat, 1:15 PM-5:15 PM<br />

Association between age, gender, residential region, and prevalence <strong>of</strong><br />

subependymal giant cell astrocytoma among patients with tuberous sclerosis<br />

complex: A U.S. Healthcare Claims Database study. Presenting Author:<br />

Michael Kohrman, University <strong>of</strong> Chicago, Chicago, IL<br />

Background: Subependymal giant-cell astrocytomas (SEGA) are slow growing<br />

non-cancerous tumors that can occur in patients with tuberous sclerosis<br />

complex (TSC). The objectives <strong>of</strong> this study were to examine SEGA<br />

prevalence among TSC patients in a real world setting, and to ascertain the<br />

relationships between SEGA prevalence and age groups, genders, or<br />

residential regions. Methods: We conducted a retrospective cohort study<br />

based on a large US commercial healthcare claims database. Patients with<br />

a TSC claim between 2000 and 2009 and with 12-month continuous<br />

enrollment after their first TSC claim were included into the study. SEGA<br />

was identified based on ICD-9CM codes in inpatient or outpatient claims.<br />

Patients’ genders, residential regions and ages <strong>of</strong> their first TSC claim and<br />

/or their first SEGA claim (if they had SEGA) were extracted from enrollment<br />

files respectively. SEGA prevalence was assessed with subgroup analyses <strong>of</strong><br />

genders, age groups <strong>of</strong> first TSC claim, and residential regions. Two-sample<br />

t tests and Chi-square tests were used to explore the relationships between<br />

SEGA prevalence and age groups, genders, or residential regions. Results:<br />

The study had 2,767 patients with a mean age <strong>of</strong> 28.5 years on their first<br />

observed TSC claim, and 55.3% were female. Among these TSC patients,<br />

7.7% had SEGA with variations by age groups <strong>of</strong> their first TSC claim (5.9%<br />

for age�1 year, 12.6% for age 1-5 years, 11.0% for age 6-10 years, 11.0%<br />

for age 11-18 years, 7.6% for age 19-25 years, and 5.1% for age 26 years<br />

or more), by genders (8.7% for males vs. 6.9% for females), and by<br />

residential regions (6.0%-11.0%). The associations between SEGA prevalence<br />

and age groups, genders or residential regions were all statistically<br />

significant with p�0.05. Conclusions: In a real world setting, and by the<br />

end <strong>of</strong> the first post-TSC year, 7.7% TSC patients had an observed SEGA<br />

diagnosis. This prevalence varied by age groups, genders, residential<br />

regions. Further research is needed to explore the factors that results into<br />

these variations.<br />

1611 General Poster Session (Board #10E), Sat, 1:15 PM-5:15 PM<br />

A retrospective analysis <strong>of</strong> all non-AIDS defining cancers (NADC): A subset<br />

analysis <strong>of</strong> the County Hospital AIDS Malignancy Project (CHAMP).<br />

Presenting Author: Shweta Gupta, John H. Stroger Jr. Hospital <strong>of</strong> Cook<br />

County, Chicago, IL<br />

Background: County Hospital (CCH) with its HIV clinic, the CORE Center<br />

(CC) is the largest provider for HIV patients (pts) in Chicago, treating over<br />

5,500 HIV pts yearly. There is paucity <strong>of</strong> data on characteristics <strong>of</strong> HIV�<br />

cancers (ca) in the inner city. The CHAMP cohort is a retrospective study <strong>of</strong><br />

all HIV associated cancers at CC and CCH over past 14 years (yrs). We<br />

analyzed all <strong>of</strong> the NADC from this cohort. Methods: All HIV pts with NADC<br />

were identified from the CHAMP cohort and retrospectively reviewed for<br />

HIV and cancer characteristics, overall survival (OS), and pt demographics.<br />

Statistics: Survival data was analyzed using Kaplan-Meier analysis and Cox<br />

Proportional Hazards model. Results: Of 438 pts identified, 157 were<br />

NADC representing 21 ca. The average (ave) age was 48 yrs (range 44-57),<br />

with prostate ca having highest age presentation. Over the past 10 yrs, the<br />

number <strong>of</strong> NADC has risen from 10 to over 20 each yr. Unlike historical<br />

controls (HC) where lung ca is most common, anal ca (21%) was most<br />

frequent followed by lung ca (17%). Prostate, head and neck (HNSCC),<br />

liver, and colorectal ca were seen in 9, 9, 8, and 7% respectively. 65% <strong>of</strong><br />

pts were African <strong>American</strong>s (AA) and 18% Caucasians. 78% <strong>of</strong> all NADC<br />

were men. 45% <strong>of</strong> anal ca present with stage IIIa/b disease, moderately to<br />

poorly differentiated ca in 48%, with a median OS <strong>of</strong> 34 mo. CD4 count did<br />

not alter OS but stage predicted better outcomes. 86% lung ca presented<br />

as stage III/IV disease with ave CD4 count 204. Histologically, 36% were<br />

SCC, 28% adenosquamous and 20% adenocarcinoma. OS was 5.5 mo and<br />

did not change by histology, CD4, or age. 68% HNSCC present with stage<br />

IVa/b but no IVc. Ave age was 48 yrs with an OS <strong>of</strong> 18mo. 50% were<br />

oropharyngeal compared to 22% in HC. Conclusions: Based on data by<br />

Sheilds et. al, CCH treats just over 1% <strong>of</strong> the country’s NADC population.<br />

We demonstrate a higher incidence <strong>of</strong> NADC over time, dominated by a<br />

younger, AA and male population. Each ca presents with advanced stage<br />

45-86% and poorly differentiated tumors ranging from 15-30%. The OS <strong>of</strong><br />

each cancer is consistent with HC with exception <strong>of</strong> HNSCC. As HIV pts age<br />

becoming prone to cancers <strong>of</strong> elderly, education and screening <strong>of</strong> inner city<br />

HIV pts will help improve cancer rates.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!